RS 102895 hydrochloride

Cat. No. 2089

RS 102895 hydrochloride C21H21F3N2O2.HCl [1173022-16-6]

Price and Availability

For RS 102895 hydrochloride pricing & availability please select your country from the drop down menu:
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 1'-[2-[4-(Trifluoromethyl)phenyl]ethyl]-spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one hydrochloride

Biological Activity

CCR2-selective chemokine receptor antagonist (IC50 values are 0.36 and 17.8 μM for inhibition of human recombinant CCR2b and CCR1 receptors respectively). Blocks MCP-1-stimulated calcium influx and chemotaxis with IC50 values of 32 nM and 1.7 μM respectively. Also inhibits α1A, α1D and 5-HT1A receptors.

Technical Data

Soluble to 75 mM in DMSO
>99 %
Desiccate at RT

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Select another batch:
Safety Data Sheet: View Safety Data Sheet


Clark et al (1983) Synthesis and antihypertensive activity of 4'-substituted spiro[4H-3,1-benzoxazine-4,4'piperidin]-2(1H)-ones. J.Med.Chem. 26 657. PMID: 6842505.

Mirzadegan et al (2000) Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists. J.Biol.Chem. 275 25562. PMID: 10770925.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

View Related Products by Product Action

Keywords: RS 102895 hydrochloride, supplier, CCR2b, chemokine, receptor, antagonists, Chemokine, Receptors, RS102895, hydrochloride, Chemokine Receptor Antagonists

Quick Order

Find multiple products by catalog number

divider line

Immunology Guide


Highlights over 190 products for immunology research. Request copy or view PDF today.

divider line

New Therapies and Challenges in Asthma

Written by Peter J. Barnes

Asthma Life Science Poster

'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development. Request copy today.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Life Science Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance. Request copy today.

divider line

New Products in this Area

MRS 2905

Potent and selective P2Y14 receptor agonist


Potent prostacyclin (PGI2) analog

S 18886

Potent thromboxane A2 (TP) antagonist


Potent Smo antagonist

ONO 8130

EP1 receptor antagonist

TC-G 1008

Potent and selective GPR39 agonist

Ro 1138452 hydrochloride

Selective prostacyclin IP receptor antagonist

Sign-up for new product e-alerts
divider line

Bio-Techne Events

Pharmacology 2015

Pharmacology 2015

December 15 - 17, 2015

London UK